exRNAdisease

General Information

Database ID:

exR0078127

RNA Name:

OAZ1

RNA Type:

mRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

2269509

End Site(bp):

2273490

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AAGAB	chr15	67200667	67255195	-
ABCB8	chr7	151028422	151047782	+
ABL2	chr1	179099330	179229684	-
AC005258.1	chr19	2269525	2341172	+
AC006030.1	chr2	74211604	74363377	-
AC008982.1	chr19	38817471	38840178	-
AC010422.3	chr19	12643831	12648397	-
AC011455.2	chr19	38915404	38949855	-
AC073508.2	chr17	40627356	40665141	-
AC104109.3	chr5	134167170	134226071	-
AC124312.1	chr15	24955034	25000276	+
ACAT2	chr6	159762045	159779112	+
ACLY	chr17	41866917	41930542	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ACTL6A	chr3	179562886	179588407	+
ACTN1	chr14	68874143	68979440	-
ACTR8	chr3	53867066	53882152	-
ADAR	chr1	154582057	154628013	-
AEN	chr15	88621337	88632281	+
AHCTF1	chr1	246839098	246931967	-
AHSA1	chr14	77457870	77469472	+
AIFM1	chrX	130129362	130165887	-
AKAP1	chr17	57085092	57121346	+
AL133352.1	chr10	100505628	100529881	-
AL139260.3	chr1	38864501	38881617	-
ALCAM	chr3	105366909	105576900	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC007952.4	chr17	19112000	19112636	-
AC009908.1	chr8	124996985	124998198	-
AC067930.1	chr8	143579636	143580670	+
AC079145.1	chr2	19990209	20004795	+
AC087392.5	chr17	795306	795794	+
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference